224 related articles for article (PubMed ID: 21472018)
1. Resistance or sensitivity of Wilms' tumor to anti-FZD7 antibody highlights the Wnt pathway as a possible therapeutic target.
Pode-Shakked N; Harari-Steinberg O; Haberman-Ziv Y; Rom-Gross E; Bahar S; Omer D; Metsuyanim S; Buzhor E; Jacob-Hirsch J; Goldstein RS; Mark-Danieli M; Dekel B
Oncogene; 2011 Apr; 30(14):1664-80. PubMed ID: 21472018
[TBL] [Abstract][Full Text] [Related]
2. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
3. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
4. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors.
Koesters R; Ridder R; Kopp-Schneider A; Betts D; Adams V; Niggli F; Briner J; von Knebel Doeberitz M
Cancer Res; 1999 Aug; 59(16):3880-2. PubMed ID: 10463574
[TBL] [Abstract][Full Text] [Related]
5. Developmental tumourigenesis: NCAM as a putative marker for the malignant renal stem/progenitor cell population.
Pode-Shakked N; Metsuyanim S; Rom-Gross E; Mor Y; Fridman E; Goldstein I; Amariglio N; Rechavi G; Keshet G; Dekel B
J Cell Mol Med; 2009 Aug; 13(8B):1792-1808. PubMed ID: 20187302
[TBL] [Abstract][Full Text] [Related]
6. Cancer. Converging on beta-catenin in Wilms tumor.
Nusse R
Science; 2007 May; 316(5827):988-9. PubMed ID: 17510350
[No Abstract] [Full Text] [Related]
7. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
[TBL] [Abstract][Full Text] [Related]
8. Berberine inhibits Wilms' tumor cell progression through upregulation of Wilms' tumor gene on the X chromosome.
Liu Y; Liu S
Mol Med Rep; 2013 Nov; 8(5):1537-41. PubMed ID: 24002362
[TBL] [Abstract][Full Text] [Related]
9. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway.
Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE
Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125
[TBL] [Abstract][Full Text] [Related]
10. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
11. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
12. Frizzled gene expression and negative regulation of canonical WNT-β-catenin signaling in mouse F9 teratocarcinoma cells.
Golenia G; Gatie MI; Kelly GM
Biochem Cell Biol; 2017 Apr; 95(2):251-262. PubMed ID: 28177772
[TBL] [Abstract][Full Text] [Related]
13. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling.
Major MB; Camp ND; Berndt JD; Yi X; Goldenberg SJ; Hubbert C; Biechele TL; Gingras AC; Zheng N; Maccoss MJ; Angers S; Moon RT
Science; 2007 May; 316(5827):1043-6. PubMed ID: 17510365
[TBL] [Abstract][Full Text] [Related]
14. Variable FZD7 expression in colorectal cancers indicates regulation by the tumour microenvironment.
Vincan E; Flanagan DJ; Pouliot N; Brabletz T; Spaderna S
Dev Dyn; 2010 Jan; 239(1):311-7. PubMed ID: 19655379
[TBL] [Abstract][Full Text] [Related]
15. Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm.
Royer-Pokora B; Busch M; Beier M; Duhme C; de Torres C; Mora J; Brandt A; Royer HD
Hum Mol Genet; 2010 May; 19(9):1651-68. PubMed ID: 20106868
[TBL] [Abstract][Full Text] [Related]
16. Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia.
Khan NI; Bradstock KF; Bendall LJ
Br J Haematol; 2007 Aug; 138(3):338-48. PubMed ID: 17614820
[TBL] [Abstract][Full Text] [Related]
17. Pathology, genetics and cytogenetics of Wilms' tumour.
Md Zin R; Murch A; Charles A
Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
[TBL] [Abstract][Full Text] [Related]
18. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.
Chung MT; Lai HC; Sytwu HK; Yan MD; Shih YL; Chang CC; Yu MH; Liu HS; Chu DW; Lin YW
Gynecol Oncol; 2009 Mar; 112(3):646-53. PubMed ID: 19095296
[TBL] [Abstract][Full Text] [Related]
19. LMP1 antagonizes WNT/β-catenin signalling through inhibition of WTX and promotes nasopharyngeal dysplasia but not tumourigenesis in LMP1(B95-8) transgenic mice.
QingLing Z; LiNa Y; Li L; Shuang W; YuFang Y; Yi D; Divakaran J; Xin L; YanQing D
J Pathol; 2011 Apr; 223(5):574-83. PubMed ID: 21394719
[TBL] [Abstract][Full Text] [Related]
20. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway.
Flahaut M; Meier R; Coulon A; Nardou KA; Niggli FK; Martinet D; Beckmann JS; Joseph JM; Mühlethaler-Mottet A; Gross N
Oncogene; 2009 Jun; 28(23):2245-56. PubMed ID: 19421142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]